Trial Profile
Clinical Outcomes With Ceftolozane-tazobactam in Patients With Multi Drug Resistant (MDR) Pseudomonas Aeruginosa Infections
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2020
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections
- Focus Therapeutic Use
- 07 Oct 2018 Results (n=25, data from 11 hospitals between Jun 2016 to Feb 2018) presented at the IDWeek 2018
- 07 Oct 2018 Results (n=65) presented at the IDWeek 2018
- 02 May 2018 New trial record